The European major medicine regulator, the European Medicines Agency (EMA), listed a new rare nerve disorder known as Guillain–Barré Syndrome (GBS) as a possible AstraZeneca COVID-19 vaccine side effect, Reuters reported on Wednesday.
EMA said that 833 GBS cases were reported from 592 million given worldwide. Therefore, EMA classified the side effect as “very rare.”
In the same context, the U.S. Food and Drug Administration (FDA) has classified GBS as a possible side-effect of Johnson & Johnson’s vaccine, which uses the same technology as AstraZeneca.
It is worthy to mention that both AstraZeneca, and Johnson & Johnson sparked concerns over causing blood clots for adults after receiving the shots.
A new study posted in July showed that the AstraZeneca COVID-19 vaccine has a small rare blood clot risk for people, who have low platelets, especially after the first dose and this possibility decreased after the second dose.
Published in the Lancet medical journal, the study found that the rate of “thrombosis” that accompanied “thrombocytopenia” syndrome after the first dose of the vaccine was 8.1 per million.
This rate decreased to 2.3 per million after receiving the second shot of the AstraZeneca vaccine.